Radiation Therapy Study for Patients with IDH Mutant Grade II or III Glioma

Clinical Trial Title

A phase II randomized trial of proton vs. photon therapy (IMRT) for cognitive preservation in patients with IDH mutant, low to intermediate grade gliomas.

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain function in patients with IDH mutant grade II or III glioma. Proton beam radiation therapy uses tiny charged particles to deliver radiation directly to the tumor and may cause less damage to normal tissue. Intensity-modulated or photon beam radiation therapy uses high-energy x-ray beams shaped to treat the tumor and may also cause less damage to normal tissue. Patients will be more likely to be randomized to proton beam radiation therapy. It is not yet known if proton beam radiation therapy is more effective than photon-based beam intensity-modulated radiation therapy in treating patients with glioma.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have tumor tissue available for submission for central pathology review.
  • Have documentation from the enrolling site confirming the presence of IDH mutation and 1p/19q status.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Aidnag Z. Diaz, MD

Contact Information

Rush Cancer Center Clinical Trials Office


Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more